Illumina and Deerfield Management, a healthcare investment organisation, have signed a five-year deal to support artificial intelligence and genomics in the development of new drugs and treatments for diseases. With the help of genomic knowledge and tools, the collaboration intends to support such programmes that have the potential to succeed. This initiative will reduce the expenses for research and development. According to the agreement, the firms will employ Illumina’s discovery platform while Deerfield provides its translational science capabilities for the pursuit of producing genetically validated drug candidates to further research discovery stage. Alex Aravanis, chief technology officer at Illumina, says that this collaboration will yield the identification and production of new drugs faster and at lower costs. He also says that new life-changing therapies will become accessible to patients.
Read More from Pharmaceutical Technology
